Apparatus and method for transdermal delivery of parathyroid hormone agents
An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
1. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a plurality of microprojections that are adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein the biocompatible coating comprises 20% PTH, 20% sucrose, 12.7% HCl, 0.2% Tween 20 and 0.03% EDTA.
2. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes at least one low volatility counterion.
3. The method of claim 2 , wherein said PTH-based agent has a positive charge at said coating formulation pH and said low volatility counterion comprises a first acid having at least one acidic pKa.
4. The method of claim 3 , wherein the amount of said low volatility counterion present in said coating formulation is sufficient to neutralize the charge of said PTH-based agent.
5. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said PTH-based agent comprises hPTH (1-34) and wherein said coating formulation comprises at least one viscosity-enhancing counterion.
6. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes a viscosity-enhancing counterion comprising an acidic counterion.
7. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes at least one buffer selected from the group consisting of ascorbic acid, citric acid, succinic acid, glycolic acid, gluconic acid, glucuronic acid, lactic acid, malic acid, pyruvic acid, tartaric acid, tartronic acid, fumaric acid, maleic acid, phosphoric acid, tricarbally acid, malonic acid, adipic acid, citraconic acid, glutaratic acid, itaconic acid, mesaconic acid, citramalic acid, dimethylopropionic acid, tiglic acid, glyceric acid, methacrylic acid, isocrotonic acid, β-hydroxybutyric acid, crotonic acid, angelic acid, hydracrylic acid, aspartic acid, glutamic acid, glycine, and mixtures thereof.
8. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes at least one antioxidant selected from the group consisting of sequestering agents and free radical scavengers.
9. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes at least one surfactant selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, sorbitan derivatives, sorbitan lauratealkoxylated alcohols, polyoxyethylene castor oil derivatives and mixtures thereof.
10. A method of treating a patient having a bone fracture comprising administering a PTH-based agent transdermally to said patient in an amount effective in treating said bone fracture, wherein said PTH-based agent is selected from the group consisting of hPTH (1-34), hPTH (1-34) salts and teriparatide,
wherein said PTH based agent is transdermally administered in a pulsatile fashion to said patient comprising the steps of:
i) providing a device comprising a microprojection member having a microprojection density of 10 to 3000 microprojections per square centimeter, said microprojections being adapted to pierce the stratum corneum of the patient; wherein a biocompatible coating is disposed on said microprojection member, said coating being formed from a coating formulation having a viscosity in the range of approximately 20-200 cp and comprising at least one PTH-based agent, and
ii) applying said microprojection member of said device to a skin site of said patient with an impact applicator, whereby said plurality of stratum corneum-piercing microprotrusions pierce the stratum corneum and deliver said PTH-based agent in a pulsatile fashion to said patient sufficient to treat said patient,
wherein said hPTH (1-34) salt is selected from group consisting of acetate, propionate, butyrate, pentanoate, hexanoate, heptanoate, levulinate, chloride, bromide, citrate, succinate, maleate, glycolate, gluconate, glucuronate, 3-hydroxyisobutyrate, tricarballylicate, malonate, adipate, citraconate, glutarate, itaconate, mesaconate, citramalate, dimethylolpropinate, tiglicate, glycerate, methacrylate, isocrotonate, β-hydroxibutyrate, crotonate, angelate, hydracrylate, ascorbate, aspartate, glutamate, 2-hydroxyisobutyrate, lactate, malate, pyruvate, fumarate, tartarate, nitrate, phosphate, benzene, methane sulfonate, sulfate and sulfonate, and
wherein said coating formulation includes at least one polymeric material having amphiphilic properties.